Report Detail
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019
- RnM3856013 |
- 20 December, 2019 |
- Global |
- 615 Pages |
- Global Markets Direct |
- Pharma & Healthcare
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 29, 19, 2, 18, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 9, 4, 6 and 3 molecules, respectively.
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development
AbbVie Inc
Agios Pharmaceuticals Inc
Altor Bioscience LLC
Arromax Pharmatech Co Ltd
Ascentage Pharma Group International
AstraZeneca Plc
Atara Biotherapeutics Inc
AUM Biosciences Pte Ltd
Bio-Path Holdings Inc
BioLineRx Ltd
Boston Biomedical Inc
Bristol-Myers Squibb Co
Cantargia AB
Celgene Corp
Celularity Inc
Daiichi Sankyo Co Ltd
Escend Pharmaceuticals Inc
Eureka Therapeutics Inc
ExCellThera Inc
Fate Therapeutics Inc
Fusion Pharma LLC
Gamida Cell Ltd
GlaxoSmithKline Plc
GlycoMimetics Inc
GT Biopharma Inc
Handa Pharmaceuticals LLC
Hebei Senlang Biotechnology Inc Ltd
HEC Pharm Co Ltd
Helocyte Biosciences Inc
HighPass Bio Inc
Housey Pharmaceutical Research Laboratories LLC
Hovione FarmaCiencia SA
Ilyang Pharmaceutical Co Ltd
ImmunoForge Co Ltd
ImmunoGen Inc
Incysus Therapeutics Inc
Incyte Corp
Inhibikase Therapeutics Inc
Johnson & Johnson
Juno Therapeutics Inc
LG Chem Ltd
MAA Laboratories Inc
Magenta Therapeutics Inc
Mana Therapeutics Inc
MedPacto Inc
Millennium Pharmaceuticals Inc
Nanjing Sanhome Pharmaceutical Co Ltd
Natco Pharma Ltd
Nemucore Medical Innovations Inc
Neovia Oncology Inc
Nohla Therapeutics Inc
Novartis AG
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
PharmaEssentia Corp
Phylogica Ltd
Prescient Therapeutics Ltd
PRISM Pharma Co Ltd
Shenogen Pharma Group Ltd
Shouyao Holding Co Ltd
SignalChem Lifesciences Corp
Stemline Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Synactix Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Terns Pharmaceuticals Inc
TheraPharm Deutschland GmbH
Xencor Inc
Xspray Pharma AB
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles
(camptothecin + podofilox) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AIC-47 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALT-803 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMX-5035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit MIR126 for Chronic Myelocytic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APG-1351 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
asciminib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATA-520 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azacitidine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
binimetinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BL-8040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Chronic Myeloid Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Hematological Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceralasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYNK-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dilanubicel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ECT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ES-3000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ET-019002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Chronic Myeloid Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Leukemias - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CD19 and CD22 for Acute Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CD19 for Blood Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CD20 for Blood Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CD22 for Blood Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target GM-CSF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-3326595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HD-30 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HND-030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HND-033 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hu8F4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICS-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMGN-632 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inotuzumab ozogamicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipilimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ivosidenib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ixazomib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTCR-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KF-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lurbinectedin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MANA-677679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGTA-456 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milademetan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MJ-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
napabucasin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nidanilimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nilotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nivolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMI-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRCAN-019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omidubicel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OTS-167 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OXS-3550 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pevonedistat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ponatinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prexigebersen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRI-724 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ProTmune - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
radotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropeginterferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-0071235 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCO-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SENL-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHC-004221A1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLC-391 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chronic Myelocytic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ABL1 for Chronic Myeloid Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ADAR1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BCR-ABL for ALL and CML - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Bcr-Abl for CML and Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SIRT1 for Chronic Myelogenous Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-1153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNG-162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUNK-0954 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SY-2755 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit STAT5 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-243 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tipifarnib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5614 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
triciribine phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Triplex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uproleselan sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target WT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vactosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
venetoclax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XmAb-14045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones
Featured News & Press Releases
Dec 10, 2019: Ascentage Pharma releases updated data of its novel BCR-ABL inhibitor, HQP1351, in an oral presentation nominated for "Best of ASH"
Nov 25, 2019: Data from Incyte’s Oncology Portfolio including ponatinib hydrochloride accepted for presentation at the 61st Annual ASH Meeting
Nov 14, 2019: Ascentage Pharma to release updated data of its novel, third-generation BCR-ABL inhibitor, HQP1351, in Chinese chronic myeloid leukemia patients in an oral presentation at the 61st American Society of Hematology Annual Meeting
Nov 06, 2019: Takeda to present abstract on ICLUSIG at 61st American Society of Hematology (ASH) Annual Meeting
Jul 21, 2019: Ascentage Pharma to initiate phase Ib stuy of HQP1351 in tyrosine kinase inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
Jul 08, 2019: SPARC receives Orphan Drug Designation from the USFDA for SCO-088 for the treatment of patients with chronic myeloid leukemia
Jun 14, 2019: Novartis presents on Asciminib at the 24th Congress of the European Hematology Association (EHA) in Amsterdam
Jun 11, 2019: Xspray granted additional product patents in the United States including HyNap-Nilo
May 16, 2019: Bristol-Myers Squibb to present new data on Sprycel at EHA 2019
Feb 19, 2019: Incyte provides statement on World Health Organization Global Medical Product alert for Iclusig (ponatinib)
Jan 18, 2019: EMA recommends extension of existing paediatric indications for Dasatinib
Jan 03, 2019: An errant editing enzyme promotes tumor suppressor loss and leukemia propagation
Dec 27, 2018: Bio-Path Holdings provides clinical update and 2019 business outlook
Dec 03, 2018: Ascentage Pharma announces oral presentation of novel, third-generation BCR-ABL inhibitor in myelogenous leukemia patients at the 60th American Society of Hematology Annual Meeting
Nov 21, 2018: Ascentage Pharma to present new clinical data at the ASH 2018 annual meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Summary:
Get latest Market Research Reports on Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). Industry analysis & Market Report on Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) is a syndicated market report, published as Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
